99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy by Hoebers, Frank J. P. et al.
ORIGINAL ARTICLE
99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging
of apoptosis in patients with head and neck cancer treated
with chemoradiotherapy
Frank J. P. Hoebers & Marina Kartachova &
Josien de Bois & Michiel W. M. van den Brekel &
Harm van Tinteren & Marcel van Herk &
Coen R. N. Rasch & Renato A. Valdés Olmos &
Marcel Verheij
Received: 22 June 2007 /Accepted: 28 September 2007 /Published online: 10 November 2007
# Springer-Verlag 2007
Abstract
Purpose The purpose of this study was to determine the
value of
99mTc Hynic-rh-Annexin-V-Scintigraphy (TAVS),
a non-invasive in vivo technique to demonstrate apoptosis
in patients with head and neck squamous cell carcinoma.
Methods TAVS were performed before and within 48 h
after the first course of cisplatin-based chemoradiation.
Radiation dose given to the tumour at the time of post-
treatment TAVS was 6–8 Gy. Single-photon emission
tomography data were co-registered to planning CT scan.
Complete sets of these data were available for 13 patients.
The radiation dose at post-treatment TAVS was calculated
for several regions of interest (ROI): primary tumour,
involved lymph nodes and salivary glands. Annexin uptake
was determined in each ROI, and the difference between
post-treatment and baseline TAVS represented the absolute
Annexin uptake: Delta uptake (ΔU).
Results In 24 of 26 parotid glands, treatment-induced
Annexin uptake was observed. Mean ΔU was significantly
correlated with the mean radiation dose given to the parotid
glands (r=0.59, p=0.002): Glands that received higher
doses showed more Annexin uptake. ΔU in primary
tumour and pathological lymph nodes showed large inter-
patient differences. A high correlation was observed on an
inter-patient level (r=0.71, p=0.006) between the maxi-
mum ΔU in primary tumour and in the lymph nodes.
Conclusions Within the dose range of 0–8 Gy, Annexin-
V-scintigraphy showed a radiation-dose-dependent uptake
in parotid glands, indicative of early apoptosis during
treatment. The inter-individual spread in Annexin uptake
in primary tumours could not be related to differences in
dose or tumour volume, but the Annexin uptake in tumour
and lymph nodes were closely correlated. This effect might
represent a tumour-specific apoptotic response.
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Apoptosis is an important mechanism of cell death in
response to treatment with radiation and many chemother-
apeutic agents [1]. To what extent apoptosis contributes to
the overall cytotoxic effect of an anti-cancer treatment
modality has been the topic of intense research during the
last decade [2–4]. The relative contribution of apoptosis to
the occurrence of cell death varies greatly both between
different tumour types and normal tissues [5].
Recently, in vivo imaging of apoptosis has proven to be
feasible by using radiolabelled Annexin V [6–10]. This
endogenous human protein has a high affinity for membrane-
bound lipid phosphatidylserine (PS), which becomes
exposed at the outer leaflet of the cell membrane bilayer
at an early stage of the apoptotic process [11, 12]. PS then
serves as a recognition site for macrophages that digest and
remove apoptotic cells. The reproducibility of the
99mTc-
Hynic-Annexin-V scintigraphy has been demonstrated in
head and neck squamous cell carcinoma (HNSCC) patients
by serial imaging in untreated patients [13] in which the
mean difference in uptake was 6%. We have recently
demonstrated that
99mTc-Hynic-rh-Annexin V scintigraphy
(TAVS) correlates with radiation-induced cytologically
confirmed apoptosis in non-Hodgkin lymphoma [14] and
can be used to identify patients that have a favourable
prognosis [15].
Thecurrentstandardofpracticeforpatientswithadvanced
stage HNSCC is treatment with concurrent cisplatin-based
chemoradiation [16, 17]. Although this is an effective
treatment, it also is accompanied by more severe toxicity
than radiation alone. We reasoned that TAVS early during
treatment might be used to monitor apoptosis induction in
tumour and normal tissue and to give an indication of the
radiosensitivity of these structures. In future, this would also
offer the possibility to adapt the treatment strategy at an
early stage on a patient-by-patient basis.
In the present study, we therefore aimed at assessing the
feasibility of TAVS as a non-invasive technique to demon-
strate treatment-induced apoptosis in vivo, in patients with
HNSCC, early during treatment with concurrent chemo-
radiation. The purpose was to determine the degree of uptake
on TAVS in normal tissue, primary tumour and lymph node
metastases and to evaluate the treatment-induced Annexin
uptake in relation to radiation dose. Furthermore, we
questioned whether the differences in uptake would correlate
with treatment response.
Materials and methods
Patients included in this study were recruited between
January 2004 and March 2005 from a randomised phase III
trial in advanced stage HNSCC, investigating the optimal
route of cisplatin delivery during cisplatin-based chemo-
radiation (RADPLAT). Randomisation was between two
treatment arms: Arm 1, standard intravenous (IV) admin-
istration of cisplatin 100 mg/m
2 (1 h before radiotherapy at
days 1, 22 and 43) or arm 2, high-dose selective intra-
arterial (IA) delivery of cisplatin at a dose of 150 mg/m
2
(on days 2, 9, 16 and 23, within 1 h after radiotherapy
delivery). Main eligibility criteria included: inoperable
squamous cell carcinoma of the oral cavity, oropharynx or
hypopharynx, TNM stage T3-4 status of primary oral cavity
or oropharyngeal tumours and T2-3-4 for hypopharyngeal
tumours, with any N-status, (functionally) inoperable
disease, no distant metastases, age at least 18 years, ability
to give informed consent and no prior cerebro-vascular
accident. Both the randomised trial and the TAVS study
were approved by the medical ethics committee of the
hospital. Patients were informed about the nature of the
study protocol and signed informed consent before enrol-
ment separately for both the randomised trial and the TAVS
protocol.
Radiotherapy was given with 4–6 MV photon linear
accelerators. Target volume included the primary tumour
and the bilateral neck for a dose of 46 Gy in 23 fractions. A
boostwas giventotheknownmacroscopictumourextensions
at the primary tumour site and lymph node metastases to a
dose of 24 Gy in 12 fractions. The total dose delivered was
70 Gy in 35 fractions, five fractions per week, with an overall
treatment time of 7 weeks. The radiation technique was either
a conventional three-field beam setup (using conventional
simulation or virtual simulation with CTscan) or an intensity-
modulated radiotherapy (IMRT) plan depending on resources
and tumour extent. The IA cisplatin delivery was accom-
plished by a selective catheterisation procedure using the
femoral artery according to the earlier described RADPLAT
protocol [18, 19]. Concurrently, with IA cisplatin sodium-
thiosulphate was administered to neutralise systemic cisplat-
in. In both arms, prehydration and posthydration were given.
99mTc-Hynic-rh-Annexin V scintigraphy, diagnostic
imaging, radiation treatment planning and image fusion
Baseline TAVS was performed within 2 weeks before the
start of concurrent chemoradiation (average interval 5 days,
range 1–8). Post-treatment TAVS was done within 48 h
after the start of cisplatin chemotherapy. At the time of
post-treatment TAVS, patients had received 6 Gy of radi-
ation in case of IV cisplatin, 8 Gy in case of IA cisplatin.
Each patient received an average of 847 MBq (range 714–
1032 MBq) of
99mTc-Hynic-rh-Annexin V (Theseus Imag-
ing Corporation, Boston, USA) by slow intravenous
injection4hb efore the planar imaging and single-photon
emission tomography (SPECT) imaging. Planar images
510 Eur J Nucl Med Mol Imaging (2008) 35:509–518were used to assess the biodistribution. SPECT of the head
and neck region was acquired by the step-and-shoot mode,
one step per 3°, 30 s per frame, matrix size 128×128, using
a dual-head gamma camera (Genesis, Philips, Best, The
Netherlands) equipped with low-energy, high-resolution
collimators. For SPECT reconstructions, an iterative algo-
rithm was used and the images were postfiltered using a
Butterworth filter (cutoff frequency 0.35, order 5). The use
of absolute quantitative analysis of SPECT data was
validated by comparison of iterative and FBP reconstruc-
tion methods. Transaxial, coronal and sagittal slices were
visually examined to evaluate tracer uptake at the tumour
sites and in normal tissues. The intensity of the obtained
images was corrected by normalisation for the injected
radioactive dose and body weight.
Baseline diagnostic imaging with MRI (1.5-T system;
Somatom; Siemens Medical Systems, Erlangen, Germany)
or spiral CT (Tomoscan AVE1, Philips, Best, The Nether-
lands or HiSpeed CT, GE Medical Systems, USA) was
performed within 3 weeks before the start of treatment and
repeated 6–8 weeks after the end of the treatment for the
evaluation of treatment response.
Radiation treatment planning was done with our clinical
treatment planning system (TPS; U-MPlan, University of
Michigan, Ann Arbor, USA). Six patients were treated by
IMRT, and the treatment plans were recalculated for the
dose at the time of first post-treatment TAVS. The regions
of interest (ROI) were delineated manually for each patient
on the CT scan. These included the gross tumor volume
(GTV) of the primary tumour and/or lymph nodes, the
parotid glands and the submandibular glands. In the other
seven patients, a standard three-field technique was used by
virtual simulation with a CT scan. In these latter patients,
the CT scan was imported into the TPS in which the
delineations were done. The treatment fields were recon-
structed, and the clinically applied dose distribution at the
time of TAVS was recalculated in the TPS. The primary
tumour and lymph node volumes were calculated by 3-D
reconstruction of the delineated GTV.
SPECT, MRI and CT were performed separately. For the
SPECT scan, we obtained reproducibility of the positioning
of the head and neck as during RT by the use of
immobilisation mask fixed to the table by adhesive tape.
All images and the radiation dose data were transferred for
image fusion to our in-house developed workstation for co-
registration (Worldmatch Workstation) in DICOM format
[20]. Keeping the limitations of the mask fixation in mind,
it was decided that for more accuracy, matching was
performed on different anatomical regions for different
ROIs, e.g. for the analysis of parotid glands or oropharyn-
geal tumours, the co-registration was done in such a way
that it ensured adequate matching for that area only. For co-
registration of ROIs in the neck (e.g. lymph nodes or
hypopharyngeal tumours), only the neck and vertebral
column was used in the matching procedure. Accurate
matching of body contours and bone structures was visually
verified. SPECT, composite SPECT/SPECT, CT and
SPECT/CT images, obtained using a colourwash technique,
were simultaneously examined using linked cursor to
evaluate Annexin V uptake in tumour and normal tissues.
The tumour and normal tissue uptake at baseline and
post-treatment were calculated as follows. ROIs were
delineated in the planning CT. Each ROI was projected
using the registration transformation onto the baseline and
post-treatment SPECT scans. The area was next sampled by
10.000 random points, and for each point, the Annexin
uptake was determined in the SPECT scans by trilinear
interpolation. Of these 10.000 samples, the maximum and
mean values were computed. In this way, the uptake in the
ROI was accurately sampled, although the pixel size in
the SPECT scans is relatively large (about 5 mm). For the
quantification of Annexin uptake, no attenuation correction
was performed because the images were obtained on a
conventional gamma camera without a hybrid system. Sub-
sequently, the difference (ΔU) between the post-treatment
and baseline uptake was determined by subtraction of the
baseline scan from the post-treatment scan. The subtraction
was performed on a point by point basis for all 10.000
points. Then, the mean or maximum value of the difference
of both scans (subtraction scan) was computed and
expressed as ΔU. No correction for background activity
was made, as this was automatically eliminated by
subtraction of the baseline activity from the post-treatment
activity, assuming that the background activity is equal in
the baseline and post-treatment scan. Radiation dose
parameters (mean and maximum dose in cGy) within each
ROI were calculated and correlated with corresponding ΔU
parameters. It was observed that the maximum ΔU and the
mean ΔU were closely related: a linear relationship between
both two parameters was found for each ROI (tumour:
r=0.93, p<0.0001; parotid gland: r=0.94, p<0.0001;
submandibular gland: r=0.90, p<0.0001; lymph node
r=0.94, p<0.0001), indicating that both values would have
been representative for the whole ROI.
Evaluation of treatment
Six to eight weeks after the end of treatment, the results of
therapy were evaluated by means of radiological inves-
tigations (by MRI or CT scan and/or ultrasound) and
examination under general anaesthesia, with biopsies taken
in case of suspicious findings. For residual disease in the
neck at the time of evaluation, salvage neck dissection was
performed if the patient was judged operable. Follow-up
visits were planned every 3 months in the first year after
therapy, every 4 months in the second year and less
Eur J Nucl Med Mol Imaging (2008) 35:509–518 511frequent thereafter. A follow-up chest X-ray was performed
annually.
Statistical analysis
For quantitative comparison of continuous data Student’s t
test was applied. Chi-squared and Fisher’s exact test were
used for analysis of categorical data. The Pearson and
S p e a r m a nr a n kc o r r e l a t i o nc o e f f i c i e n tr were used to
calculate correlations between Annexin uptake and treat-
ment parameters. Locoregional control and survival data
were calculated from the start of treatment using the
Kaplan–Meier method and log rank testing. Two-sided
P values of <0.05 were considered statistically significant.
Results
Sixteen patients gave their consent for participating in the
TAVS study. However, one patient refused post-treatment
TAVS scans; in one patient, no CT scan in radiation
treatment position was available, and in one patient, co-
registration with SPECT was unsuccessful due to misalign-
ment because no immobilisation mask and no tongue
Fig. 1 Sagittal projection of TAVS imaging co-registered with
planning CT scan. The solid line represents the contour of the patient
during RT-planning CT scan, including tongue depressor. The
projected image is the TAVS. a Baseline TAVS; b post-treatment
TAVS. Note the mismatch of contours of the head and neck mostly
due to different position of the chin in b. The misalignment of the
lower neck in a is due to the flexion of the neck. For the analysis, the
matching procedure was focused on the mandibular region. This
patient was excluded from analysis because of misalignment in b
Table 1 Patient, tumour and treatment characteristics
Patient
number
Gender Age
(years)
Tumor site TNM
stage
Tumor
volume
(cm
3)
Max ΔU in
primary
tumour
Interval cisplatin
infusion and
Annexin scan (h)
RT technique Mode of cisplatin
administration
1 M 64 Oral cavity III 21 62 52.2 Conventional 3 field Intra-arterially
2 M 58 Oropharynx III 47 203 50.3 IMRT Intra-arterially
3 F 65 Oropharynx IV 25 112 53.1 IMRT Intra-arterially
4 M 55 Oropharynx III 26 36 53.5 IMRT Intra-arterially
5 M 49 Hypopharynx II 13 43 53.3 IMRT Intra-arterially
6 F 66 Oral cavity IV 32 135 53.6 Conventional 3 field Intra-arterially
7 M 60 Oropharynx IV 147 191 54.3 Conventional 3 field Intra-arterially
8 M 46 Oropharynx IV 28 170 52.7 Conventional 3 field Intra-arterially
9 M 55 Oropharynx IV 41 42 49.9 IMRT Intravenously
10 M 57 Oropharynx IV 25 51 51.7 IMRT Intravenously
11 M 48 Oropharynx IV 91 117 51.5 Conventional 3 field Intravenously
12 M 50 Hypopharynx IV 100 132 50.3 Conventional 3 field Intravenously
13 M 26 Oropharynx IV 105 52 50.1 Conventional 3 field Intravenously
M Male, F female, IMRT intensity modulated radiotherapy
512 Eur J Nucl Med Mol Imaging (2008) 35:509–518depressor could be used during SPECT due to pain (Fig. 1).
The number of patients included in this analysis on
99mTc-
Hynic-rh-Annexin V scintigraphy in advanced stage
HNSCC is therefore 13. The mean age of patients was
53 years (range 26–66 years). See Table 1 for the patient,
tumour and treatment characteristics.
Annexin uptake in normal tissue and tumour
At baseline scintigraphy, reproducible physiologic Annexin
uptake was detected on the planar images in liver, kidneys,
spleen, gall bladder, bone marrow, colon and urinary
bladder, as described earlier [7, 14, 21].
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Fig. 2 Baseline (diamonds) and
post-treatment (squares)
Annexin activity in parotid
glands (a), submandibular
glands (b) and tumour (c) for all
13 patients. The data for 26
parotid and submandibular
glands represent the right and
left gland within each patient
Eur J Nucl Med Mol Imaging (2008) 35:509–518 513In the parotid glands, weak baseline uptake was present
in all cases. The post-treatment TAVS showed moderate to
strong increase in uptake in 24 of 26 parotid glands
(Fig. 2a). The average of the mean number of counts
increased from 55 to 88 (p<0.001). Visual analysis of the
increase in uptake showed that these changes were related
to the radiation portals and the dose given to the parotid
glands (Fig. 3). The difference in Annexin uptake between
the post-treatment and baseline TAVS (ΔU) in each parotid
gland was correlated with the radiation dose at the time of
post-treatment scintigraphy (n=13 patients, n=26 parotids).
The mean ΔU showed a positive correlation with the mean
radiation dose (Pearson coefficient r=0.59, p=0.002):
parotid glands that received a higher dose of radiation
showed a higher Annexin uptake (Fig. 4a). The increase in
Annexin uptake in parotid glands that were treated with
parotid-sparing IMRT was less than in parotid glands that
were treated with a conventional three-field technique
(IMRT 29 counts, three-field technique 59 counts, p=0.02).
The given radiation dose at the time of post-treatment
TAVS (6 or 8 Gy) and the mode of cisplatin administration
(IA or IV) did not affect the uptake in parotid glands. As
xerostomia scoring was not documented sufficiently de-
tailed in the files, we interviewed patients alive at last
follow-up for xerostomia grading for the purpose of this
study. In nine patients alive at last follow-up, the treatment-
induced Annexin uptake in parotid glands was related to the
subjective xerostomia rating using the EORTC QLQ HN-35
questionnaire [22]. No relation could be established in this
small set of patients (data not shown).
For the submandibular glands, a similar pattern as with
the parotids was observed: absent/weak baseline uptake and
moderate to strong increase after the start of chemoradiation
(Fig. 2b). The average of the mean number of counts
increased from 85 to 132 (p<0.001). No correlation bet-
ween the ΔU and radiation dose was noted (Fig. 4b),
probably as all submandibular glands were located within
the high-dose region.
The baseline TAVS showed moderate to strong Annexin
uptake in the primary tumour in all patients, indicative of
spontaneous apoptosis or necrosis. On the post-treatment
TAVS, the uptake in tumour clearly increased in nine cases;
in the other four, little or no changes occurred (Fig. 2c). The
average of the maximum number of counts increased from
Fig. 3 TAVS imaging co-regis-
tered with planning CT scan in
frontal plane and axial plane, a
and c at baseline, b and d after
treatment, from patient number
2. The Annexin uptake is repre-
sented by colourwash. In b and
d, the isodose lines show the
dose distribution in relation to
the parotid gland and primary
tumour (isodose lines shown,
40, 60, 80 and 95% from outer
to inner side of patient). Note
the increased treatment-induced
Annexin uptake in the right
parotid gland, in correspondence
to the higher radiation dose
distribution, when compared to
the left parotid gland. Also note
the weak increase in primary
tumour Annexin uptake in the
right oropharynx after treatment
and in the anterior floor of
mouth (d)
514 Eur J Nucl Med Mol Imaging (2008) 35:509–518127 to 163 (p=0.007). The difference between post-
treatment and baseline TAVS (ΔU) in primary tumour was
not correlated with primary tumour volume (Pearson
coefficient r=0.39, p=0.21) nor with the mode of chemo-
therapy administration (p=0.21). In nine patients, 17 lymph
node metastases were present in the neck (mean lymph node
volume 5 cm
3,r a n g e1 –19). The treatment-induced Annexin
uptake (maximum ΔU) in primary tumour was positively
correlated with the uptake in corresponding lymph node
metastases (r=0.73, p=0.004) as shown in Fig. 5.T ov e r i f y
that the observed effects of Annexin uptake in different
structures could not be attributed solely to the administered
radioactive dose per patient but was tissue-specific, we
calculated the correlation between the ΔU in tumour and
parotid glands. No evidence of such an effect was found
(r=0.28, p=0.18).
Response to treatment, locoregional control and survival
The median follow-up of all patients alive at last follow-up
was 30 months (range 24–38). The complete response (CR)
rate at the primary tumour site was 85%. CR rate in the
neck in the case of nodal metastases was 100%. The overall
CR rate was 85%. The estimated locoregional (LR) tumour
control rates were 68% at 2 and 3 years. The rates for
disease-free survival (DFS) were 54% at 2 and 3 years.
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Fig. 4 Correlation plot of mean
radiation dose (cGy) and the
post-treatment increase in
Annexin uptake, mean ΔU,i n
parotid glands (a), normalised
for tracer dose and body weight.
Circles represent parotid glands
treated with IMRT, triangles
parotids treated with conven-
tional technique. In b, the cor-
relation between mean radiation
dose (cGy) and the post-treat-
ment increase in Annexin up-
take, mean ΔU,i n
submandibular glands is given
Eur J Nucl Med Mol Imaging (2008) 35:509–518 515Overall survival (OS) rates at 2 and 3 years were 62 and
40%, respectively. In this small subset of 13 patients from a
larger randomised phase III trial, there were no differences
in response rates, LR control, DFS or OS between the two
treatment arms (IV vs IA). No correlation could be
established between baseline or treatment-induced Annexin
uptake (ΔU) and any outcome parameter (response rate,
recurrences and/or survival).
Discussion
This study represents our first clinical experience on in vivo
imaging of apoptosis with TAVS in HNSCC patients in
which we applied co-registration of multiple imaging
modalities. By this, we were able to analyse treatment-
induced changes in normal and tumour tissue, early during
therapy, after one cycle of cisplatin chemotherapy and 6–
8 Gy of radiotherapy. Treatment-induced Annexin uptake in
the parotid glands could be visualised, indicative of early
treatment related apoptosis at mean radiation doses as low
as 3–8 Gy (see Fig. 4a) and one course of cisplatin. The
Annexin uptake in the parotids showed a radiation dose-
response relationship: Glands that had received higher
doses of radiation demonstrated increased Annexin uptake.
Loss of parotid gland function, leading to xerostomia, is
an important long-term side effect of radiotherapy, affecting
quality of life of patients. It has well been shown by
scintigraphy studies [23] and by salivary flow rate studies
[24] that reduction of radiation dose to the parotid glands
can maintain parotid function, decrease xerostomia and
improve quality of life. Most studies on salivary gland
function are performed after a full course of RT (typically
60–70 Gy in 6–7 weeks) [23–26]. Our study design with
early in vivo imaging indicated that already after low dose
of RT (6–8 Gy), parotid glands may be affected and that the
physiologic process leading to loss of parotid gland func-
tion already starts early. This is in agreement with obser-
vations in experimental rodent studies in which apoptosis
was induced early, after doses of up to 5 Gy [27]. Similar
results were obtained in a monkey model, with early
radiation induced apoptosis of serous acinar cells of
salivary glands [28]. It was suggested that these early
effects are mainly responsible for the acute sialoadenitis,
which, at higher RT doses, might progress in chronic
xerostomia by damage to and depletion of ductal stem cells
within the gland. In the nine patients assessed for
xerostomia, no relation could be established with subjective
salivary gland function after radiotherapy and parotid gland
Annexin uptake. However, the significance of this analysis
is limited, as we assessed both parotid glands separately by
TAVS, and xerostomia questionnaires give an overall im-
pression of function. We did not include follow-up salivary
flow studies. In short, our results indicate indirect evidence
of early radiation-induced salivary gland damage and, in
future studies, this needs to be correlated with functional
outcome parameters.
Due to the large inter-patient variability in the baseline
TAVS (Fig. 2c), the subtraction method for assessing
treatment-induced changes was chosen over a relative
method (e.g. percentage change). In this figure, it is
important to notice that the maximum uptake value of the
baseline and post-treatment scan might be located in
different points within the tumour ROI. Therefore, these
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Fig. 5 Correlation plot of the
treatment-induced increase in
Annexin uptake, maximum ΔU,
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node metastases. Each colour
represents an individual patient.
Some patients had multiple
lymph node metastases originat-
ing from the same primary tu-
mour. In these cases, multiple
values of treatment-induced
Annexin uptake in lymph nodes
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single value of the primary
tumor (on the x-axis)
516 Eur J Nucl Med Mol Imaging (2008) 35:509–518data cannot be simply subtracted, but for the calculation of
the maximum ΔU in primary tumour and lymph nodes, the
baseline scan was first subtracted from the post-treatment
scan, and, subsequently, these parameters were calculated
from the subtraction scan. The treatment-induced Annexin
uptake in primary tumour and pathological lymph nodes
showed a positive correlation: Patients with primary
tumours with a high Annexin uptake also appeared to have
lymph node metastases with high Annexin uptakes. The
ΔU in primary tumour and lymph node metastases showed
large inter-patient differences (Fig. 5). This variation could
not be attributed to differences in the route of cisplatin
administration (intravenous or intra-arterial chemoradia-
tion), nor to the radiation doses given (6 or 8 Gy), nor to
the primary tumour volume. This positive correlation for
ΔU in primary tumour and lymph nodes as well as the
large inter-patient differences might represent a tumour-
specific apoptotic response.
In our series, repositioning of the patient during SPECT
scan in RT position was standard procedure, but due to the
limitations in fixation, not optimal. The repositioning
facilitated the co-registration of SPECT and CT scan. In
one patient, misalignment occurred because the positioning
was not accurate due to the fact that the RT position could
not be reproduced (Fig. 1). So, for co-registration of (func-
tional) imaging to RT-planning CT scan data in HNSCC,
we recommend improvements from our protocol to obtain a
reproducible positioning, like the use of an immobilisation
mask fixed to the SPECT table, the use of the same
mattress under the patient and a laser alignment system. In
ongoing studies, we have now incorporated these. In the
current series, no attenuation correction was applied be-
cause the images were obtained on a conventional gamma
camera without a hybrid system. For the purpose of this
study, the quantification of Annexin uptake remains valid,
as we used the relative increase from baseline to post-
treatment uptake, and the degree of attenuation will be
equal on both scans.
In this small series of HNSCC, the treatment-induced
Annexin uptake (ΔU) in primary tumour did not predict
outcome: No correlation between Annexin uptake and early
response was observed probably partly due to the high
initial response rates (85%). In addition, TAVS also did not
predict the locoregional control rates within the first 2 years
of follow-up. In our previous experience on TAVS in other
tumour sites (mainly lymphoma), a strong correlation has
been found between early response (within 3 months) and
Annexin uptake [15]. One explanation for the lack of
correlation might be that in the current series, these
advanced stages HNSCC with large tumours harbour more
necrosis, which is also detected by TAVS because of
accessibility of PS at the necrotic cell membrane [29].
Van de Wiele et al. [8] showed that in HNSCC, Annexin
scintigraphy correlated with histopathological apoptosis
(using TUNEL assay) only in the absence of necrosis.
Indeed, in this series, baseline Annexin uptake in the
HNSCC patients was clearly demonstrated, whereas it was
not present in our previous study in lymphoma patients
[15]. This may suggest the presence of necrosis in large
tumours from solid origin. Other factors that may affect
Annexin uptake are the intra- and peri-tumoural lympho-
cyte infiltration [30]. For the future, we plan to increase the
number of HNSCC patients to undergo the TAVS imaging
to prove whether or not it can be used for outcome
prediction as it was shown in patients with malignant
lymphoma and non-small cell lung cancer [14, 15].
In conclusion, co-registration of Annexin V scintigraphy
with radiotherapy-planning CT scan showed a radiation-
dose-dependent uptake in parotid glands, indicative of early
apoptosis during treatment. The inter-individual spread in
Annexin uptake in primary tumours could not be related to
differences in treatment schedule or tumour volume, but the
Annexin uptake in tumour and lymph nodes were closely
correlated. This effect might represent a tumour-specific
apoptotic response.
Conflicts of interest None declared.
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